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ABSTRACT
Magnetic Halloysite Nanotubes can be used in multiple ways in combating
growth of osteosarcoma. The adsorption ability of the inner and outer surfaces of
halloysite nanotubes allows for attachment of different molecules, including anti-cancer
drugs, polymer layering for controlled drug release, and magnetic coating. This magnetic
coating would allow for cell membrane disruption, hyperthermia, and for targeting of
specific tissue. In this project, the goal was to create these magnetic nanotubes and test
their cytotoxicity against stem cells and osteosarcoma cells.
To create these magnetic nanotubes, we used electrodeposition to adsorb ferrous
oxide nanoparticles (FeNPs) onto halloysite nanotubes (HNTs) to create iron-coated
halloysite nanotubes (FeHNTs). These FeHNTs were then imaged using a field emission
scanning electron microscope (FESEM) and underwent elemental analysis, using the
energy dispersive X-ray spectroscopy (EDS), to ensure placement of the FeNPs onto the
HNTs.
The FeHNTs were then tested for their cytotoxicity and cell differentiation
potential against human adipose-derived mesenchymal stem cells (hASCs) and mouse
osteosarcoma cells. The viability of both cell lines was compared. Next, the proliferation
capability, the potential tissue formation, and the potential ossification of hASCs was
compared with increasing concentrations of FeHNTs.
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CHAPTER 1
INTRODUCTION

1.1

Treating Osteosarcoma

Osteosarcoma, formerly a grim diagnosis, is still a particularly dangerous form of
cancer that requires diligent observation and aggressive treatment. Presenting as a form
of abnormal growth, commonly seen in the long bones of the patient, it can cause
significant pain and swelling of the area, as well as potentially causing fracture of the
bone [1]. If left to metastasize, it has a high chance to become present in the lungs, which
will reduce the percentage of survival for the patient [1,2].
Originally, the treatment of osteosarcoma involved the complete amputation of
the affected limb. Current treatment has advanced, requiring resection of the tissue
affected as well as pre- and post-resection chemotherapeutic treatments. The usage of
multiple anti-osteosarcoma agents has shown to improve patient outcomes as well.
Unfortunately, resection of the affected tissue requires the removal of healthy tissue near
the affected area, to ensure that there is no recurrence of the cancer [1,2]. Such methods
require the patient to undergo further medical procedures in order to restore healthy tissue
to the affected area. Should the cancer be present again in the same area while the patient
is recovering, there is little that can be done to eliminate it and further prevent recurrence.
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1.2

Magnetic Nanomaterial

I theorize that through a novel magnetic material, there is potential for a magnetic
nanomaterial to be developed that would be used to help combat and prevent growth of
osteosarcoma cells, as well as help support the growth of cells necessary to allow for
healthy tissue growth. In this paper, I will explore how this magnetic nanomaterial was
developed and tested for cell viability for normal cells and osteosarcoma cells, as well as
the cell proliferation and tissue formation for the normal cells.

CHAPTER 2
BACKGROUND

2.1
2.1.1

Literature Review

Osteosarcoma
Osteosarcoma is an aggressive cancer that has the potential to kill the affected

patient within months. It is also tenacious, with recurrence of the disease occurring in 2030% of patients in which the cancer is localized. Should the disease undergo metastasis,
the recurrence rate increases to 80%. With the addition of adjuvant chemotherapy, patient
outcomes have increase from an 11% survival rate to a 61% survival rate, depending
upon the stage of the cancer [2]. Should the cancer metastasize in the lungs, which occurs
in 85% of cases, the survival rate decreases greatly [1]. However, localized hyperthermia
has been studied for use in aiding chemotherapeutic treatments. In one study, patients had
a notable increase in their two- and four-year survival rate. In fact, 51 patients out of the
343 patients in the studied showed no detectable disease after treatment, compared to 46
patients showing no detectable disease for chemotherapeutic treatment alone [3].
Diagnosis of potential osteosarcoma sites are necessary in developing an effective
treatment plan. Use of radiography and CT scans allow for efficient imaging of not only
the affected site, but the type of osteosarcoma affecting the patient. Intraosseous
osteosarcoma is the most common form, being highly aggressive in destroying the
cortical bone. It is common to find malignant masses in adjacent tissues [4].
3
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Even with the increase in survival rate, there is still the necessity for tissue
reconstruction after the required resection of affected tissue. Usually, during resection, a
significant amount of healthy tissue is taken with the affected tissue to reduce the chance
of recurrence. Afterward, tissue reconstruction surgery is performed, and the patient
cannot undergo chemotherapy until the wound is healed, which takes a minimum to 2 – 3
weeks [2]. To combat osteosarcoma more efficiently, the usage of a material that allows
for healthy cell growth while limiting osteosarcoma growth is necessary.
2.1.2

Magnetism and Iron Nanoparticles
Currently, there are many uses for magnetics and iron nanoparticles (FeNPs),

especially in imaging. For instance, dextran coated FeNPs are used in as a contrast agent
for MRIs, being biocompatible and can be excreted after imaging [5]. As well, these
same nanoparticles can be used for tracking stem cells using MRI or even causing
migration of these stem cells [6, 7]. In multiple studies performed by Xia, et al., they
were able to show that magnetic fields, in conjunction with FeNPs, were able to enhance
the osteogenic activity of stem cells [8-10]
Magnetics can also potentially be used to combat osteosarcoma growth. In Shen
et al., 2016, the authors state that there are many studies that show that electromagnetic
field (EMF) exposure can induce many different methods of cell death. In particular, the
authors wanted to see the effects exposure to a weak magnetic field would have on
macro-autophagy, the ability for the cell to “eat” itself. The authors used Chinese hamster
lung (CHL) cells divided into three groups: a positive control group that was treated with
4-nitroquinoline 1-oxide (4NQO) and underwent no exposure to EMF, a group exposed
to EMF, and a group exposed to offset EMF called the “sham group”. The cell culture
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conditions were 37 ºC and 5% CO2 for all groups, including during EMF exposure
testing. It was found that presence of LC3 markers was high after EMF exposure for 24
hours, signaling the presence of autophagic activity. As well, exposure to EMF did cause
the surface properties of the cells to change. However, exposure to the EMF did not cause
double strand breaks in the cell nucleus and could not induce apoptosis in the target cells
[11].
In another study, researchers showed that EMF exposure can influence growth
and viability of cancer cells. Authors in Ashdown et al., 2020 theorized that pulsed
magnetic fields would have a damaging effect to cancer cells while leaving normal cells
alone due to influencing the behavior of the glycocalyx. It has been shown that cancer
cells produce more glycosaminoglycans (GAGs) and glycoproteins due to an abnormal
glycocalyx. Knowing this, authors used the human lung carcinoma cell line A549, human
lung lymphatic endothelial cells (hLEC), Lewis lung carcinoma (LLC) cells, and human
breast carcinoma cells (MDA-MB-231). Using a solenoid magnet connected to a circuit
to create the necessary pulses for the magnetic fields, all four cell lines were exposed to
EMF with a gauss meter used to measure EMF strength. Immediately after being exposed
to EMF at frequencies of 50 and 385 Hz and field strength of 20 mT, A549 cells
presented protease outside of the cell membrane. This would dictate that the cell
membrane had ruptured and was leaking. Shown in Figure 2, the EMF pulses lowered the
viability and cell growth of A549 cells. MDA-MB-231 and LLC cell lines showed similar
releases of protease, indicating the rupture of the cell membrane. However, hLECs, the
only non-cancer cell line and the cell line that would be found near lung adenocarcinoma,
showed no differences between the control and the EMF exposed samples in terms of cell
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proliferation and viability. This would show that regular cells may very well be able to
resist the effects that EMF pulses had on cancerous cells [12].
2.1.3

Magnetic Halloysite Nanotubes
The addition of halloysite nanotubes (HNTs) allows for an expansion of uses for

magnetism and iron nanoparticles. One of these uses is controlled and sustained drug
delivery. In Fizir, et al., 2017, the authors showed a potential delivery system using
magnetic nanoparticles and HNTs. The authors first simulated the interactions between
four different monomers and the antibiotic drug Norfloxacin (NOR), settling on the two
monomers that had the highest interaction energies. Following simulation of the materials
to determine the best composition for the drug delivery, the authors were able to use the
HNTs’ negatively charged outer surface to attach the positively charged iron ions by
adding the HNTs in deionized water with dissolved ferric chloride hydrate (FeCl3•6H2O)
and ferrous sulfate hydrate (FeSO4•7H2O) to create magnetic HNTs (MHNTs). Authors
then dissolved NOR in acetic acid to allow NOR to attach to the outer surface of the
MHNTs. They then coated the NOR-MHNTs with ethylene glycol dimethacrylate
(EGDMA) and either methacrylic acid (MAA) or acrylamide (AM), to allow for
sustained release of NOR. The authors successfully showed that the release of NOR
could be controlled by pH difference, that the release of NOR could be sustained by the
composition and concentration of polymers attached to the surface of the NOR-MHNTs,
and that the MHNTs could be successfully moved and held by way of magnetism [13].
Antibiotics are not the only drug that can be used in targeted and sustained drug
release. In Dramou et al., 2018, researchers were able to use MHNTs to deliver
Camptothecin (CPT), an antitumor drug that can be used against a variety of cancers.
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CPT itself is difficult to administer, necessitating the need for a delivery system. Using
a method similar to Fizir, et al., 2017 to develop MHNTs, the authors then added the
MHNTs to a chitosan oligosaccharide (COS) solution so that COS could be added to the
outer surface of the MHNTs (COS/MHNTs). Next, the authors dissolved 1-ethyl-3(dimethylaminopropyl) carbodiimide (EDC) and folic acid (FA) in phosphate buffered
saline (PBS), then added the MHNTs into the solution (FA-COS/MHNTs). The FACOS/MHNTs were separated from the PBS and washed with distilled water then freezedried. Finally, CPT was added to the FA-COS/MHNTs to created CPT@FACOS/MHNTs. Through magnetic testing, the authors were able to prove that the FACOS/MHNTs had a magnetic field similar to that of Fe nanoparticles. At pH 5, the FACOS/MHNTs were able to almost release CPT completely in a sustained manner over
three days. It was also seen that higher concentrations of FA-COS/MHNTs had worse
cell viability against human epithelial colorectal adenocarcinoma cells (Caco-2). It is
important to note that in this case, worse cell viability would be preferred against Caco-2
cells. Given this information, CPT that wasn’t attached to FA-COS/MHNTs had better
outcomes than CPT@FA-COS/MHNTs. However, given the difficulty of administering
free CPT to a patient, the near similar efficacy of CPT@FA-COS/MHNTs to free CPT,
and the sustained release controlled by pH, this study demonstrates that the FACOS/MHNTs would make for a sufficient delivery system for anticancer treatment [14].
2.1.4

Stem Cells and Regenerative Medicine
Due to the need for surgical resection to take a large amount of healthy tissue, this

requires the patient to undergo reconstructive therapies to replace the taken tissue. As
stated before, continuation of chemotherapeutic treatments requires that the surgical
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wound be healed first. This necessity opens an avenue for the use of regenerative
medicine to allow the patient to heal and start chemotherapy quicker.
Regenerative medicine often requires the use of stem cells from the patient to
facilitate repair of the damaged tissue. Originally, mesenchymal stem cells (MSCs)
derived from patient bone marrow were used for this endeavor. In fact, bone-marrowderived MSCs are still used as standard for which stem cells can be used to replace the
multiple tissues of the body. MSCs can differentiate into many different cell types, able
to undergo osteogenesis, adipogenesis, and chondrogenesis, among others, given
environmental conditions [15, 16].
Given the proximity of the extraction area for bone-marrow-derived MSCs and
the difficulty and pain associated with retrieval, there would be a need to choose a new
tissue to derived MSCs from. Adipose-derived MSCs (hASCs) supply a way to easily and
safely extract MSCs through lipoaspiration. In addition to the ease of extraction, hASCs
are very proliferative and able to differentiate into the same cell lines as bone-marrowderived MSCs, making them incredibly useful for regenerative medicine, as well as tissue
reconstruction after surgical resection [17 – 19].
Currently, there are many examples for the use of MSCs in the regeneration of
lost tissue. For instance, Mills et al. [20] describes the use of composite hydrogels to
influence the differentiation and placement of hASCs. Hydrogels encompass a variety of
materials that can be used in biomedical applications, with the ability to be developed
with a broad range of mechanical and chemical properties. Such materials create
microenvironments that can significantly influence cell behavior, as well as acting as a
scaffold for tissue regeneration. To even further influence cell behavior, other materials
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can be added to the hydrogel. This could not only allow for quick proliferation and
differentiation of the hASCs but can also allow for limiting microbial infection or even
allowing for sustained drug delivery to the area [20].

CHAPTER 3
IRON-COATED HALLOYSITE NANOTUBES

3.1

Introduction

Iron-coated Halloysite Nanotubes (FeHNTs) provide a unique and cost-effective
material for the potential to combat cancerous growth.
3.2
3.2.1

Materials and Methods

Ferrous Oxide Nanoparticles
Ferrous Oxide (Fe3O4), also known as magnetite, has interested scientists

throughout the ages due to its significant magnetic properties. Containing equal amounts
of iron (II) oxide (FeO) and iron (III) oxide (Fe2O3), Fe3O4 presents the unique property
of ferrimagnetism [21]. Ferrimagnetism is present when the electronic spins are
antiparallel (directions are parallel but going in opposite directions), but the magnitude of
the spins are different and do not cancel each other [22]. This is due to the two different
iron oxides’ positioning in Fe3O4 crystal structure. This allows for ferrimagnetism to
present like ferromagnetism, the classic and most known form of magnetism.
Ferrimagnetic materials are naturally attracted to magnets and have the potential to
become permanent magnets themselves.
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3.2.2

Halloysite Nanotubes
Halloysite nanotubes (HNTs) have been gaining more usage in biomedicine due

to their inherently low toxicity, significant biocompatibility, and their able to adsorb
different materials due to the different charges of their outer surface and inner lumen.
With a length in the range of 0.5 – 1.5 µm, an inner lumen between 10 – 20 nm, and an
outer diameter of 40 – 70 nm, HNTs provide a structure that is large enough to hold a
significant amount of material and small enough to be used without detriment to cells and
tissues [23].
HNTs are rolled sheets of aluminosilicate sheets, with the inner lumen containing
aluminol groups and the outer surface containing silicate groups. This unique structure
causes the inner and outer surfaces to have different charges, with the inner surface
having a positive charge and a pH of around 8.5, and the outer surface having a negative
charge and a pH of around 1.5 [24]. These surfaces charges can also be enhanced or
reduced to the pH of the environment the HNTs are in. This is useful in the adsorption of
different materials to the surfaces of the HNTs, with the materials being adsorbed
positioning itself on the surface of with the corresponding charge.
HNTs are also non-cytotoxic, making them perfect carriers for a multitude of
drugs, especially cancer drugs. This has been shown in many cases such as in Karewicz
et. al. [25], where researchers were able to adsorb Artemisinin, Methotrexate, and
Taurolidine, all of which are anti-osteosarcoma drugs, onto the surface of HNTs [25]. In
Dramou et. al. [14], where researchers were able to adsorb Camptothecin, an anti-colon
cancer drug, to the surface for magnetic HNTs. In addition to loading Camptothecin on
the surface of the HNTs, researchers were able to layer different polymers to the surface
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for sustained delivery of the drug to the affected area [14]. Finally, HNTs are
significantly inexpensive, costing between $600 and $3000 depending upon the
application [26].
3.2.3

Development of Iron-Coated Halloysite Nanotubes
Electrodeposition is a relatively simple method of attached nanoparticles to the

surface of an HNT. A one-liter beaker was filled with 700 mL of distilled water at a
temperature between 80 – 90 °C. Electrodes attached to a 120 V power supply and a
stainless-steel stirrer were then added to the beaker, and the water was stirred at around
120 rpm. The stainless-steel stirrer was used instead of a magnetic stirrer to avoid the
FeNPs becoming magnetized to the bottom of the beaker or the stirrer. HNTs and FeNPs
were then ground together using a pestle and mortar. This is shown in Figure 3-1. When
sufficiently ground and mixed, the FeNPs and HNTs were then poured into the water and
the power supply turned on.
Every five minutes, the power supply would be shut off and the electrodes
switched to allow a change in the electrical field of the beaker. This process was done six
times in the process. After the end of the final five minutes, the power supply and the
stirrer were shut off. The beaker was allowed to cool for five minutes, allowing the
material to settle to the bottom of the beaker. Afterward, the supernatant was removed,
and the material washed three times with distilled water, then dried at 50°C.
3.2.4

Iron-Coated Halloysite Nanotube Characterization
The resulting material was then imaged using the Hitachi S-4800 FESEM. First,

the material was set on carbon tape then blown with puffs of air to dislodge loose
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Figure 3-1: Illustration of electrodeposition setup.
material. Afterward, a small magnet was hovered above the material to remove any loose
material from the carbon tape. Once it was shown that the material was sufficiently
attached to the carbon tape, the material was then layered with 5 nm of gold. This gold
layer was used to reduce charging, and subsequent heating, of the potential material.
Finally, the material was then placed in the SEM and imaged with an emission current of
9 μA, an accelerating voltage of 3 kV, and a working distance of 8.3 mm. Measurements
of the material was taken using ImageJ.
After imaging, the sample then underwent elemental analysis using the Hitachi S4800 FESEM’s Energy Dispersive X-ray Spectroscopy (EDS) system. The analysis used
the same conditions as the SEM imaging, except the accelerating voltage was set to 15
kV. Elemental analyses were taken for both the imaged area, as well as specific points in
the area.
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3.2.5

Iron-Coated Halloysite Nanotube Magnetic Testing
After characterization of the material was performed with SEM-EDS analyses, the

material, as well as FeNPs and a Nickel standard, were then tested for magnetization
using a Vibrating Sample Magnetometer. This test would show the magnetization of the
sample when introduced to a magnetic field with a strength in the range of -10 to 10
kGauss. This would result in the hysteresis curve for each material for comparison.
3.3
3.3.1

Results and Discussion

Characterization
Through SEM analysis, the deposition of FeNPs on the outer surface of HNTs

was shown as probable, due to the morphology of the HNTs themselves. Apart from the
abnormal amount of aggregation of the HNTs, the HNTs also had irregular shapes on the
outer surface, showing potential FeNP coating, shown in Figure 3-2. The potential
FeHNTs showed an average length of 852.5 nm and a standard deviation of 228.1 nm,
and an average width of 79.6 nm and a standard deviation of 13. 7 nm.

Figure 3-2: Scanning electron microscope image of iron-coated halloysite nanotubes.
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EDS analysis confirmed the presence of FeNPs on the surface of the HNTs.
Confirmation was shown by elemental maps showing the locations of the FeNPs on the
surfaces of the HNTs, as well as through the intensity of the x-ray dispersion from the
targeted area, shown in Figure 3-3.

Figure 3-3: Energy dispersive X-ray spectroscopy map of iron-coated halloysite
nanotubes.
3.3.2

Magnetic Testing
Magnetic testing through the Vibrating Sample Magnetometer showed a

magnetization of 64.177 emu/g in a magnetic field of 10 kGauss, a magnetization of
-64.657 emu/g in a magnetic field of -10 kGauss, and an average magnetization of 0
emu/g in a magnetic field of 0 kGauss. This, in fact, proved to have greater magnetization
then the nickel standard, but less magnetization then the FeNP control, possibly due to
the presence of HNTs. The hysteresis curve showed that the material is, in fact, a
ferrimagnetic material, as seen in Figure 3-4.
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Figure 3-4: The magnetization curves of an iron-coated halloysite nanotube sample and
an iron nanoparticle sample compared to a nickel standard.

CHAPTER 4
CELL CULTURE STUDIES

4.1

Introduction

While Fe-HNTs are potentially useful in multiple biomedical applications, it must
be confirmed if the material is cytotoxic against osteosarcoma and healthy cells, and if it
provides a bias towards differentiation of stem cells into certain cell types. To do this, the
cells must be cultured and studied for viability, proliferation, and differentiation.
4.2
4.2.1

Materials and Methods

Cell Lines
The two cell lines used for culturing were human adipose-derived mesenchymal

stem cells (hASCs) and mouse osteosarcoma (CRL-2836). hASCs were chosen for their
ability to be able to undergo osteogenesis, adipogenesis, myogenesis or chondrogenesis
[27]. Both cell lines were also chosen due to their relatively availability and ease of
culturing.
4.2.2

Cell Culture Media
The culture media is a mixture of 89% v/v Dulbecco’s Modified Eagle Medium

(DMEM), 10% v/v Fetal Bovine Serum (FBS), and 1% v/v Penicillin and Streptomycin,
totaling to a volume of 500 mL per batch. DMEM is a medium that is often used for cell
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lines of those types, while FBS is commonly used to grow different cell lines. Penicillin
and Streptomycin are commonly used to protect cells from bacterial infection.
4.2.3

Cell Culturing
Each cell line was defrosted and suspended in 15 mL of culture media before

being seeded, at a density of 5e5 cells per mL, in a T75 flask. The cells were placed in an
incubator at a temperature of 37 °C, humidity at 95%, and CO2 at 5%. Every two days the
media was drained from the flask and replaced with 15 mL of fresh culture media. When
the cells reach 80% confluence, they were passaged using 5 mL of Phosphate-Buffered
Serum (PBS) to wash the cells, then 0.5% Trypsin to detach the cells from the surface of
the flask. They were then passaged into 2-4 different T75 flasks. Cells were used for cell
seeding in all assays after Passage 3. Cells leftover from seeding were frozen and stored
in -80 °C freezer. The serial dilution to create all concentrations of the FeHNTs in media
is shown in Table 4-1.
4.2.4

Cell Proliferation Assay
Cell proliferation assays were performed on hASCs to measure increases in cell

populations within two weeks. The cells were placed into 48-well culture plates at a cell
density of 1e6 cells per mL of culture medium (5,000 cells per well). The samples were
separated by material and concentration. FeHNTs were compared against FeNPs and
HNTs, all at concentrations of 5, 10, and 20 µg/mL. As a negative control, cells
were placed in culture wells with pure culture media. Each sample was repeated three
times, holding 200 µL of media. Every two days, the culture media was drained then
replaced with 200 µL of fresh media.
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Table 4-1: Serial dilution of iron-coated halloysite nanotubes to make 20 mL of each
concentration.
Label

Concentration

FH2K
FH100
FH50
FH20
FH10

2 mg/mL
0.1 mg/ml
0.05 mg/mL
0.02 mg/mL
0.01 mg/mL

FeHNTs
(mg)
40
-

FH2K
(mL)
1
-

FH100
(mL)
10
4
2

Media
(mL)
20
19
10
16
18

Assays were performed using the CyQUANT™ Cell Proliferation Assay (C7026)
on 1, 7, and 14-days after cells were inserted into wells. To create the reagent for the cell
proliferation assay, 1 mL of the cell-lysis buffer and 50 µL of CyQUANT™ GR dye was
put into 19 mL of distilled water, then vortex. The dye, buffer, and the reagent were
protected from light.
When the cells were ready to assay, the plate was drained of media then blotted
on paper towels, then frozen in –80 °C for 24 hours to cause cell lysis. The cells were
then thawed to room temperature, and then the 200 µL of the reagent was added to each
well and incubated at room temperature for five minutes, protected from light. The cells
were then put into the fluorescence microplate reader and then evaluated at 490 nm and
540 nm for excitation and emission maxima, respectively.
4.2.5

Viability Assays
In addition to the cell proliferation assays, viability assays were performed on

both hASCs and mouse osteosarcoma cell lines. These were performed with 48-well
plates and a seeding density of 1e6 cells per mL of culture medium (5,000 cells per well)
for hASCs and a seeding density of 5e5 cells per mL of culture medium (2,500 cells per
well) for the mouse osteosarcoma cell line. These assays also had the samples separated
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by material and concentration, with FeHNTs, FeNPs, and HNTs at concentrations of 5,
10, and 20 µg/mL going against cells seeded in pure media. Each well held 200 µL of
media, and all samples were repeated three times. Every two days, the media was drained
and then replaced with 200 µL of fresh media.
Assays were performed using the Biotium Viability/Cytotoxicity Assay Kit for
Animal Live & Dead Cells (30002-T) at 1, 3, 5, and 7 days after cell seeding. This assay
was chosen for is stains: Calcien AM that only stains living cells and Ethidium
Homodimer III (EthD-III) that only stains dead cells. Calcien, when viewed using
fluorescence microscopy, glows green when attached to cells. EthD-III, on the other
hand, stains the cells red. To create the staining solutions, 5 µL of Calcien AM and 20 µL
of EthD-III was placed into 10 mL of PBS then vortexed, protected from light.
When ready, the assays were drained of culture media, then washed twice with
PBS before adding 200 µL of staining solution to each well. It was then covered with tin
foil, then incubated at room temperature for 45 minutes before being imaged using a
fluorescence microscope, the FITC filter for viewing the live cells, and the TexasRed
filter for viewing dead cells. Cell counts for each were done using ImageJ.
4.2.6

Picrosirius Red Assay
In an effort to understand if hASCs were differentiating and what tissue they were

differentiating into, Picrosirius Red assays were performed. These assays were performed
in 24-well assays. Instead of comparing different materials are different concentrations to
FeHNT, these assays focused on FeHNT at four different concentrations: 10, 20, 50, and
100 µg/mL, all of which were compared against cells in pure culture media. Each sample
was repeated three times. Cells were seeded in each well at 5e5 cells per mL of culture
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media (2,500 cells per well). Each well held 500 µL of media, and the media was
replaced with fresh media every two days.
The assays were dyed with the Picrosirius Red stain from ScyTek Laboratories at
1, 7, and 14 days. Picrosirius Red Stain is used to evaluate potential connective tissues,
with the stain being red when staining collagen fibers, and becoming yellow when
staining muscle fibers or cytoplasm. Before the stain can be used, however, the cells must
be fixed using 2-4% paraformaldehyde for 10-20 minutes.
After fixing, cells were rehydrated using 500 µL of distilled water for 30 seconds.
The distilled water is removed, then 500 µL of the Picrosirius Red stain was added to
each well, then incubated at room temperature for 60 minutes. The wells were then rinsed
twice with 0.5% acetic acid and rinsed once with absolute alcohol. The samples were
then dehydrated with absolute alcohol, in well for 15 seconds, before imaging with a
phase contrast microscope. After imaging, the stain was then removed from the cells
using 10% acetic acid, then its absorbance was measured using an absorbance microplate
reader at a wavelength of 490 nm.
4.2.7

Alizarin Red S Assay
In addition to Picrosirius Red assays, Alizarin Red S assays were performed to

evaluate potential tissue development. These assays were performed in 24-well assays.
Instead of comparing different materials are different concentrations to FeHNT, these
assays focused on FeHNT at four different concentrations: 10, 20, 50, and 100 µg/mL, all
of which were compared against cells in pure culture media. Each sample was repeated
three times. Cells were seeded in each well at 5e5 cells per mL of culture media (2,500
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cells per well). Each well held 500 µL of media, and the media was replaced with fresh
media every two days.
The assays were dyed with the Alizarin Red S stain from VitroView Biotech at 1,
7, and 14 days. Alizarin Red S stain is used to evaluate potential osteogenic activity, with
the stain becoming red when in the presence of calcium. Before the stain can be used,
however, the cells must be fixed using 2-4% paraformaldehyde for 10-20 minutes.
After fixing, cells were rehydrated using 500 µL of 70% alcohol for 30 seconds,
then rinsed in distilled water. The distilled water is removed, then 500 µL of the Alizarin
Red S stain was added to each well, then incubated at room temperature for 5 minutes.
The wells were then rinsed twice with 0.5% acetic acid and rinsed once with absolute
alcohol. The samples were then dehydrated with absolute alcohol, in well for 15 seconds,
before imaging with a phase contrast microscope. After imaging, the stain was then
removed from the cells using 10% acetic acid, then its absorbance was measured using an
absorbance microplate reader at a wavelength of 405 nm.
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4.3
4.3.1

Results and Discussion

Cell Proliferation Assay
Initially, the hASCs had higher cell populations when treated with HNTs, FeNPs,

and FeHNTs, with the cell populations increasing greatly from the Day 1 to the Day 7
assays. However, when assayed at Day 14, the increase in cell proliferation had sharply
declined, with most of the materials and concentrations having lower cell populations
than the control assays. However, the sample containing 5 µg/mL FeNPs had a higher
cell population than the control. This is shown in Figure 4-1.
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F20

FH5
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Figure 4-1: Comparison of cell proliferation when samples are exposed to different
materials (iron nanoparticles, halloysite nanotubes, and iron-coated halloysite nanotubes)
and concentrations of those materials over 14 days.
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4.3.2

Viability Assays
Throughout the week, the viability of the hASCs that were treated with FeHNTs

were close to the viability of the control samples. There was much more variation for
cells treated with FeNPs and HNTs. HNTs showed lower viability than the control
sample. However, for all samples, treated or control, the viability started to drop around
Day 5. This is shown in Figure 4-2, Figure 4-3, and Figure 4-4. Given that all cells,
treated or control, showed a drop in viability, a drop in proliferation after Day 7, and that
both assays were done at cells seeded at 5,000 cells per well, it can be concluded that the
materials were not the cause of the drops in viability and proliferation, but such drops
were caused by over-confluence of hASCs.

Control

100%

5 μg/mL

10 μg/mL

20 μg/mL

Viability

90%

80%

70%

60%

50%
Day 1

Day 3

Material

Day 5

Day 7

Figure 4-2: Comparison of the viability of human adipose-derived mesenchymal stem
cells treated with different concentrations of iron-coated halloysite nanotubes over seven
days.
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Figure 4-3: Comparison of the viability of human adipose-derived mesenchymal stem
cells treated with different concentrations of iron nanoparticles over seven days.
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Figure 4-4: Comparison of the viability of human adipose-derived mesenchymal stem
cells treated with different concentrations of halloysite nanotubes over seven days.
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Figure 4-5: Comparison of Osteosarcoma viability subjected to different concentrations
of iron-coated halloysite nanotubes over seven days.
This is somewhat confirmed with the mouse osteosarcoma cells as they had lower
cell seeding density (2,500 cells per well) and did not show a drop in viability for any of
the materials or concentrations, except for the control cells. Osteosarcoma showed a
much higher viability after Day 5 when treated with FeHNTs. This is also seen with
FeNPS, possibly showing a correlation between iron and an increase in osteosarcoma
viability. This is shown in Figure 4-5, Figure 4-6, and Figure 4-7.

27
100%
Control

5 μg/mL

10 μg/mL

20 μg/mL

90%

Viability

80%

70%

60%

50%
Day 1

Day 3

Day 5

Day 7

Material

Figure 4-6: Comparison of Osteosarcoma viability subjected to different concentrations
of iron nanoparticles over seven days.
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Figure 4-7: Comparison of Osteosarcoma viability subjected to different concentration of
halloysite nanotubes over seven days.
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Figure 4-8: Phase contrast images of Picrosirius Red Stain for control cells (left column),
cells treated with 10 µg/mL (mid-left column), 20 µg/mL (middle column), 50 µg/mL
(mid-right column), and 100 µg/mL (right column) iron-coated halloysite nanotubes on
Day 1 (top rom), Day 7 (middle row), and Day 14 (bottom row).
4.3.3

Picrosirius Red Assay
From Day 1 to Day 7, FeHNTs with higher concentrations had higher absorbance,

showing an increase in cells for those samples. Viewing the imaging for all samples
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Figure 4-9: Comparison of Picrosirius Red absorbance when human adiposederived mesenchymal stem cells are exposed to concentrations of 10, 20, 50, and
100 µg/mL of iron-coated halloysite nanotubes over 14 days.
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shows initial beginnings of tissue formation for Day 1, potential collagen development at
Day 7, and potential collagen maturation at Day 14. This is shown in Figure 4-8, and
absorbance is shown in Figure 4-9.
4.3.4

Alizarin Red S Assay
Throughout the two weeks, negligible amounts of osteogenic activity were

viewed, with a negligible amount of calcium viewed in the Day 14 assays. With the low
osteogenic activity, increasing only slightly within Day 14, and the potential collagen
development and maturation on Day 7 and Day 14, it is possible that the hASCs were
undergoing chondrogenesis. Images of the Alizarin Red S assays showed like assays
viewed in Tzortzaki et al., 2006 and Gleeson et al., 2010 [28,29]. This is shown in Figure
4-10, and absorbance is shown in Figure 4-11.

Figure 4-10: Phase contrast images of Alizarin Red S Stain for control cells (left
column), cells treated with 10 µg/mL (mid-left column), 20 µg/mL (middle column), 50
µg/mL (mid-right column), and 100 µg/mL (right column) iron-coated halloysite
nanotubes on Day 1.
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Figure 4-11: Comparison of Alizarin Red S absorbance when human adipose-derived
mesenchymal stem cells are exposed to concentrations of 10, 20, 50, and 100 µg/mL of
iron-coated halloysite nanotubes over 14 days

CHAPTER 5
DISCUSSION

5.1

Development of Iron-Coated Halloysite Nanotubes

The use of magnetics has been shown to potential to allow for more effective
methods to combat osteosarcoma. As such, the development of magnetic nanoparticles
could further increase this efficacy and increase patient survivability as well. The
development of FeHNTs allows for magnetic nanomaterials that can also be used for
controlled drug delivery. This could prove invaluable to not only combating
osteosarcoma, but in reducing potential infections and increasing tissue regeneration after
surgery. With reduced time of recovery, post-surgical chemotherapy can begin, further
eliminating osteosarcoma cells.
The electrodeposition method allows for quick and easy attachment FeNPs to
HNTs. The method requires equipment that is not expensive to acquire, with materials
that are simple to use and non-cytotoxic. The procedures are easy to perform with little
danger to who is developing. Purification of the materials is also very simple, while also
allowing for further purification procedures to be added later, should said procedures be
needed for more specialized applications. The resulting FeHNTs show the wanted
properties from both the HNTs and FeNPs. The iron-coating of the FeHNTs allow for the
material to present the ferrimagnetic properties of the FeNPs, while also allowing for the
adsorption properties of HNTs. This would allow for sustained and controlled drug
31
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delivery, allowing for anti-cancer drugs to be used before and during wound healing,
further increase efficacy.
5.2

Cytotoxicity and Differentiation Potential of FeHNTs
For both hASCs and mouse osteosarcoma cells, FeHNTs showed little to no

cytotoxicity, allowing for cell populations and viability to increase, sometimes further
than the control cells that weren’t treated with FeHNTs. While not limiting the viability
and proliferation of osteosarcoma cells is not favored, the material properties of the
FeHNTs will allow for greater efficacy in combating cancer cells while not inadvertently
damaging the healthy cells. Given the ability for hASCs to proliferate quickly and to be
easily and safely be retrieved, as well as its potential to be differentiated into tissues that
comprise most of the body, this allows for easier tissue regeneration.
FeHNTs also shows little bias for differentiation, with potential chondrogenesis
being shown in experiments. Should different growth factors be used, there is no
evidence showing that the FeHNTs would prevent differentiation into other types of
tissues. In fact, due to the FeHNTs ability to adsorb different molecules on the surface,
this could allow for a controlled development of bone tissues should the FeHNTs with
adsorbed growth factors be used in a calcium phosphate cement (CPC) scaffold [9, 10].
5.3

Future Research
FeHNTs present great potential for combating osteosarcoma. There should be

further investigation into using FeHNTs in tissue scaffolds, as the tissue scaffolds do
allow for the ability to quickly regenerate lost tissue, as well as their effect on vital
organs. This material, due to its unique properties in combating cancerous growth and
tissue healing, could potential be used to combat other cancers. Osteosarcoma is usually
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adherent, as are other sarcomas, lymphomas, melanomas, and carcinomas. Cancer cells
had already been shown to be negatively affected by oscillation of a magnetic field in in
Ashdown et al., 2020, where the authors we able to rupture the cells membrane of three
different types of carcinoma cells while lymphatic endothelial cells were unaffected [12].
As well, the ability to cause hyperthermia should be further examined. For
instance, if medical personnel are able to surround malignant growth with the FeHNTs,
there could be a way to detach the growth by causing the outer cells to undergo necrosis.
This would cause little to no damage to healthy tissue, while also removing most
cancerous cells in one procedure. The uptake of FeHNTs by cancerous and healthy cells
must be examined before this method can be examined.
Finally, the addition of anti-cancer drugs to FeHNT for use in neoadjuvant
chemotherapy treatments should be examined, as the combination of hyperthermia and
anti-cancer drugs can allow for much more efficiency in combatting cancer cell growth
and limiting its spread outside the localized region [3]. With the rupturing of cancer cell
membranes, this could provide a treatment that may not need surgical resection and make
surgical reconstruction and tissue regeneration a much easier task.
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